Mechanism of action of factor VIIa in the treatment of coagulopathies.
(2006) In Seminars in Thrombosis and Hemostasis 32 Suppl 1(Suppl. 1). p.77-85- Abstract
- Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse... (More)
- Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse bleeding triggered by extensive surgery or trauma. The general mechanism of action of rFVIIa to induce hemostasis under these conditions may be its capacity to generate a tight fibrin hemostatic plug through increased thrombin generation. A tight fibrin plug will aid in resisting the overwhelming local release of fibrinolytic activity triggered by vast tissue damage occurring in extensive trauma. Local fibrinolytic activity also occurs in the gastrointestinal tract as well as during profuse postpartum bleeding. Pharmacologic doses of rFVIIa induce hemostasis in these cases also. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/157049
- author
- Hedner, Ulla LU
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- thrombin, posttraumatic bleeding, generation, bleeding disorders, recombinant factor VIIa, hemophilia
- in
- Seminars in Thrombosis and Hemostasis
- volume
- 32 Suppl 1
- issue
- Suppl. 1
- pages
- 77 - 85
- publisher
- Georg Thieme Verlag
- external identifiers
-
- wos:000237454100009
- scopus:33646487022
- pmid:16673269
- ISSN
- 1098-9064
- DOI
- 10.1055/s-2006-939557
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- bfb6c0e0-5bfe-496a-8fec-f755bb2231f8 (old id 157049)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16673269&dopt=Abstract
- date added to LUP
- 2016-04-01 15:29:54
- date last changed
- 2022-01-28 05:38:09
@article{bfb6c0e0-5bfe-496a-8fec-f755bb2231f8,
abstract = {{Recombinant factor VIIa (rFVIIa) has been developed for treatment of bleeding in patients with hemophilia who have inhibitors against factor VIII (FVIII) or FIX, and has been found to induce hemostasis during major orthopedic surgery. The use of rFVIIa treatment for hemophilia is a new concept and is based on the low-affinity binding of FVIIa to the surface of thrombin-activated platelets. Administration of pharmacologic doses of exogenous rFVIIa enhances thrombin generation on the platelet surface at the site of injury independently of the presence of FVIII or FIX. Pharmacologic doses of rFVIIa induce hemostasis not only in hemophilia patients, but also in patients with thrombocytopenia, functional platelet defects, and with profuse bleeding triggered by extensive surgery or trauma. The general mechanism of action of rFVIIa to induce hemostasis under these conditions may be its capacity to generate a tight fibrin hemostatic plug through increased thrombin generation. A tight fibrin plug will aid in resisting the overwhelming local release of fibrinolytic activity triggered by vast tissue damage occurring in extensive trauma. Local fibrinolytic activity also occurs in the gastrointestinal tract as well as during profuse postpartum bleeding. Pharmacologic doses of rFVIIa induce hemostasis in these cases also.}},
author = {{Hedner, Ulla}},
issn = {{1098-9064}},
keywords = {{thrombin; posttraumatic bleeding; generation; bleeding disorders; recombinant factor VIIa; hemophilia}},
language = {{eng}},
number = {{Suppl. 1}},
pages = {{77--85}},
publisher = {{Georg Thieme Verlag}},
series = {{Seminars in Thrombosis and Hemostasis}},
title = {{Mechanism of action of factor VIIa in the treatment of coagulopathies.}},
url = {{http://dx.doi.org/10.1055/s-2006-939557}},
doi = {{10.1055/s-2006-939557}},
volume = {{32 Suppl 1}},
year = {{2006}},
}